AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26501118
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment (lansoprazole, clarithromycin, metronidazole)
Trial: 23596810
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng extract (1500 mg)
Trial: 18585631
Drug: Ofloxacin administration
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin administration after each BCG instillation
Trial: 16864926
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist (CAA) - verapamil
Trial: 16864926
Drug: Beta-blocker (BB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (BB) - bisoprolol, atenolol or metoprolol
Trial: 11156042
Drug: PLA barrier
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA barrier in combination with DFDBA
Trial: 9196381
Drug: L‐NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (3 mg/kg administered i.v. over 5 minutes)
Trial: 29605319
Drug: 5-hydroxy-l-tryptophan (5-HTP)
RxNorm normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxy-l-tryptophan (5-HTP) 1 mg/kg
Trial: 29605319
Drug: 5-hydroxy-l-tryptophan (5-HTP)
RxNorm normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxy-l-tryptophan (5-HTP) with negative DCAD diet
Trial: 23098865
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg daily for 10 days
Trial: 19443519
Drug: Ismigen (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ismigen (one capsule daily for the first 10 days of three consecutive months)
Trial: 11966949
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg acutely, 12.5 mg daily for 7 days)
Trial: 11966949
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg acutely, 80 mg daily for 7 days)
Trial: 9846467
Drug: Self-administered ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered ciprofloxacin eardrops at home, n = 40 (48 ears)
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered alone (750 mg) as control treatment
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered 5 to 10 minutes after antacid (30 ml)
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered 2 hours after antacid (30 ml)
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered 4 hours after antacid (30 ml)
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered 6 hours after antacid (30 ml)
Trial: 2598571
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered 2 hours after ranitidine (200 mg)
Trial: 241181
Drug: Intermittent dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosage schedules of antipsychotic preparations with reduced antiparkinsonic agents
Trial: 241181
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of chlorpromazine
Trial: 28804124
Drug: Imatinib (IM)
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib (IM) at 400 mg/day
Trial: 26441006
Drug: risperidone or
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone or flupenthixol long acting injection
Trial: 21267072
Drug: Pyronaridine-artesunate (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyronaridine-artesunate (target dose 7.2:2.4 mg/kg to 13.8:4.6 mg/kg) once daily for three days
Trial: 21267072
Drug: Chloroquine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (standard dose) once daily for three days
Trial: 16223754
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray (100 microl per dose)
Trial: 15349002
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg buprenorphine sublingual
Trial: 15349002
Drug: i.v./sublingual placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v./sublingual placebo
Trial: 15349002
Drug: escalating i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalating i.v. buprenorphine (2, 4, 8, 12, and 16 mg)
Trial: 11185667
Drug: i.v. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration
Trial: 15349002
Drug: sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual administration
Trial: 15349002
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg i.v. dose
Trial: 11739135
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 microg twice a day
Trial: 11739135
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of detection and treatment
Trial: 3617996
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy with MTX and 5-FU (therapy arm A)
Trial: 3617996
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (therapy arm B)
Trial: 26997579
Drug: APF530 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APF530 500 mg subcutaneously
Trial: 22427029
Drug: Topical spray
RxNorm normalized name: Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spray with 10% lignocaine and xylometazoline drops
Trial: 18407376
Drug: Standardized volume/weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized volume/weight-based dose reformulation
Trial: 12529662
Drug: Hypoplasia period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoplasia period after induction therapy
Trial: 10462235
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis (aP) vaccine
Trial: 8690109
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GNRH‐a) therapy
Trial: 1750588
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg dihydrocodeine
Trial: 1750588
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg dihydrocodeine
Trial: 17152744
Drug: Luteinising hormone
RxNorm normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinising hormone releasing hormone (100 microg, i.v.)
Trial: 17152744
Drug: Thyrotropin (TSH)
RxNorm normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin (TSH) releasing hormone (200 microg, i.v.)
Trial: 17152744
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (.1 U/kg, i.v.)
Trial: 31548349
Drug: Higher plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher plasma 25(OH)D levels (top quintile ≥24.1 ng/mL)
Trial: 26179619
Drug: Liraglutide 1.8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8mg (dose escalated from 0.6 and 1.2mg/day for 1 week each)
Trial: 19540671
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine injections
Trial: 17468774
Drug: Pre-emptive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive antibiotic therapy (cefepime administered when neutropenia developed)
Trial: 17468774
Drug: Pre-emptive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive antibiotic therapy (cefepime)
Trial: 17468774
Drug: Empiric antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotic therapy (cefepime administered at onset of fever and neutropenia)
Trial: 1684991
Drug: PPA/B (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA/B (75 mg phenylpropanolamine and 12 mg brompheniramine)
Trial: 7139401
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg . kg‐1
Trial: 19884613
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch plus nicotine lozenge
Trial: 26444330
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT - 660 nm, 30 mW, continuous regime, fluency of 10J/cm2) with orthoses
Trial: 16139175
Drug: Haloperidol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (up to 8 mg/day)
Trial: 10223219
Drug: Sticking plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sticking plaster treatment
Trial: 7595911
Drug: Nitrendipine (27.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (27.3 mg daily)
Trial: 7595911
Drug: Mefruside (30.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefruside (30.7 mg daily)
Trial: 26767505
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg daily for 24 weeks combined with NB-UVB
Trial: 26767505
Drug: NB-UVB monotherapy
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB-UVB monotherapy
Trial: 25185628
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor physical therapy (PFPT) biweekly until 12 weeks postoperatively
Trial: 23059199
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (started at study entry)
Trial: 23059199
Drug: Deferred antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred antiretroviral therapy (started when CD4 percentage declined to less than 15%)
Trial: 15570025
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (26 +/- 5 g soy protein containing 44 +/- 8 mg isoflavones/d)
Trial: 15570025
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate + probiotic capsules (10^9 colony-forming units Lactobacillus acidophilus DDS-1 and Bifidobacterium longum)
Trial: 15570025
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein isolate (26 +/- 5 g milk protein/d)
Trial: 15570025
Drug: Soy treatments
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy treatments in hypercholesterolemic women (TC > 5.17 mmol/L)
Trial: 11482548
Drug: Creatine (3x5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (3x5 g x day(-1))
Trial: 11482548
Drug: Iso-nitrogenated placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso-nitrogenated placebo (3x10 g x day(-1))
Trial: 7919354
Drug: 150 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/m2 busulfan
Trial: 7919354
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg busulfan
Trial: 2448408
Drug: Conjugated oral
RxNorm normalized name: linoleic acids, conjugated Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated oral estrogens (0.625 mg daily)
Trial: 2448408
Drug: Conjugated oral
RxNorm normalized name: linoleic acids, conjugated Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated oral estrogens (1.25 mg daily)
Trial: 2448408
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered estradiol (25 micrograms/24 hr)
Trial: 2448408
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered estradiol (50 micrograms/24 hr)
Trial: 2448408
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered estradiol (100 micrograms/24 hr)
Trial: 2448408
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered estradiol (200 micrograms/24 hr)
Trial: 30478263
Drug: Low medication
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low medication adherence
Trial: 28677237
Drug: Topical Vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Vitamin B12-barrier cream (MB12)
Trial: 28677237
Drug: Standard glycerol-petrolatum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glycerol-petrolatum-based emollient cream (GPC)
Trial: 26511956
Drug: Motavizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motavizumab (15 mg/kg, five monthly intramuscular doses)
Trial: 24386076
Drug: Initial colposcopy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial colposcopy with biopsies and/or subsequent treatment based on colposcopic and histological findings (n = 1696)
Trial: 24386076
Drug: Cytological surveillance
RxNorm normalized name: OTOLOGICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytological surveillance (six-monthly tests; n = 1703)
Trial: 21228029
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (3.5 mg/kg cumulative dose over 96 weeks)
Trial: 21228029
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (5.25 mg/kg cumulative dose over 96 weeks)
Trial: 12895265
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) for 1 year
Trial: 12895265
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) at the end of treatment
Trial: 12895265
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN alpha)-2b at the end of treatment
Trial: 10646156
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam 1 mg before surgery
Trial: 10646156
Drug: No sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sublingual lorazepam
Trial: 9015118
Drug: Rota colostrum
RxNorm normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rota colostrum (20 ml for 2 weeks)
Trial: 6626699
Drug: Methylprednisolone capsule
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone capsule (1 g)
Trial: 6626699
Drug: Methylprednisolone suspension
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone suspension (1 g)
Trial: 6626699
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of methylprednisolone
Trial: 6626699
Drug: High-dose pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pulse therapy
Trial: 31556655
Drug: Supportive psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychodynamic therapy (SPT)
Trial: 25065424
Drug: Ketamine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 8 mg·kg(‐1)
Trial: 25065424
Drug: Dexmedetomidine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 3 μg·kg(‐1)
Trial: 25065424
Drug: Dexmedetomidine 4
RxNorm normalized name: DEXMEDETOMIDINE 4MCG/ML/NS INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 4 μg·kg(‐1)
Trial: 25065424
Drug: Dexmedetomidine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 5 μg·kg(‐1)
Trial: 20923996
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily or 30 mg twice daily)
Trial: 17919551
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 3 weeks before surgery
Trial: 11226788
Drug: Heparin-surface-modified (HSM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-surface-modified (HSM) PMMA IOL (811C, Pharmacia)
Trial: 10806662
Drug: Metformin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (oral administration for 8-12 weeks)
Trial: 8282323
Drug: Fludrocortisone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.4 mg/d) treatment with ad libitum diet
Trial: 8282323
Drug: Fludrocortisone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.4 mg/d) with a 150 mmol/24 h sodium diet
Trial: 179286
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid analogue (antilipolytic agent)
Trial: 179286
Drug: Isoprenaline infusion
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline infusion (control for dogs)
Trial: 30268158
Drug: Low-frequency electrostimulation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency electrostimulation (ES) administered via CarebandR device on unilateral PC6 acupoint.
Trial: 26303188
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (OM)
Trial: 22951287
Drug: TAS-102 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 (35 mg/m² orally twice a day in a 28-day cycle)
Trial: 11009140
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg rifampicin
Trial: 8866630
Drug: Histamine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (1% solution) microinjection
Trial: 8866630
Drug: Histamine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (1% solution) combined with oral intake of 20 mg cetirizine
Trial: 1324483
Drug: Glucomannan fibers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan fibers (DICOMAN 5:2‐3 gr/die), 2-3 caps twice a day
Trial: 31895174
Drug: Sublingual morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual morphine (10 mg)
Trial: 31895174
Drug: Swallowed morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowed morphine (10 mg)
Trial: 27888177
Drug: Novartis Access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Novartis Access NCD medicines provided through public and private non-profit health facilities.
Trial: 27888177
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no access to Novartis Access NCD medicines).
Trial: 22344549
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ondansetron 8 mg orodispersible tablet
Trial: 22344549
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of ondansetron 8 mg orodispersible tablet
Trial: 17682078
Drug: One-on-one peer
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-on-one peer support (treatment group, n = 37)
Trial: 10453931
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g oral ganciclovir daily for 8 weeks